Phenotypic disruption to orofacial movement topography in conditional mutants with generalized CamKIIa/Cre D1Tox versus striatal-specific DARPP-32/Cre D1Tox ablation of D1 dopamine receptor-expressing cells

Synapse

Volumn 65, Issue 9, 2011, Pages 835-842

  Tomiyama, Katsunori ^a   Kim, Hyun Ah ^b   Kinsella, Anthony ^c   Ehrlich, Michelle E ^d   Schütz, Günter ^e   Koshikawa, Noriaki ^a   Lawrence, Andrew J ^b   Waddington, John L ^c   Drago, John ^b  

^a NIHON UNIVERSITY   (Japan)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Dopamine receptors; Huntington's disease; Orofacial

Indexed keywords

DOPAMINE 1 RECEPTOR; PHOSPHOPROTEIN DARPP 32;

ARTICLE; CAMKIIA GENE; CELL LOSS; CELL PROLIFERATION; FEMALE; FOREBRAIN; GENE; HUMAN; HUNTINGTON CHOREA; JAW MOVEMENT; MALE; MOVEMENT (PHYSIOLOGY); OROFACIAL MOVEMENT; PHENOTYPE; PRIORITY JOURNAL; TOPOGRAPHY;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CORPUS STRIATUM; DIPHTHERIA TOXIN; DOPAMINE AGONISTS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOSE-RESPONSE RELATIONSHIP, DRUG; FACE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOVEMENT; MOVEMENT DISORDERS; MUTATION; NEURONS; PEPTIDE FRAGMENTS; PHENOTYPE; RECEPTORS, DOPAMINE D1; TIME FACTORS;

EID: 79959589854     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20910     Document Type: Article

References (31)

1. Alexander GE, Crutcher MD. 1990. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci 13: 266-271.
2. Arning L, Saft C, Wieczorek S, Andrich J, Kraus PH, Epplen JT. 2007. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet 122: 175-182.
3. 1 dopamine receptor-expressing cells. Behav Brain Res 206: 78-87.
4. Bhidayasiri R, Truong DD. 2004. Chorea and related disorders. Postgrad Med J 80: 527-534.
5. Bogush AI, McCarthy LE, Tian C, Olm V, Gieringer T, Ivkovic S, Ehrlich ME. 2005. DARPP-32 genomic fragments drive Cre expression in postnatal striatum. Genesis 42: 37-46.
6. Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. 2006. Seminar on choreas. Lancet Neurol 5: 589-602.
7. Clark GT. 2006. Medical management of oral motor disorders: Dystonia, dyskinesia and drug-induced dystonic extrapyramidal reactions. J Calif Dent Assoc 34: 657-667.
8. 2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum. Neuroscience 39: 59-67.
9. Di Maio L, Squitieri F, Napolitano G, Campanella G, Trofatter JA, Conneally PM. 1993. Onset symptoms in 510 patients with Huntington's disease. J Med Genet 30: 289-292.
10. Desbonnet L, Waddington JL, O'Tuathaigh CM. 2009. Mice mutant for genes associated with schizophrenia: Common phenotype or distinct endophenotypes? Behav Brain Res 204: 258-273.
11. 1A dopamine receptors. Proc Natl Acad Sci USA 20: 12564-12568.
12. 1 dopamine receptor neurons by cre-mediated site-specific recombination. J Neurosci 18: 9845-9857.
13. Friedlander AH, Mahler M, Norman KM, Ettinger RL. 2009. Parkinson disease: Systemic and orofacial manifestations, medical and dental management. J Am Dent Assoc 140: 658-669.
14. 1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. Proc Natl Acad Sci USA 104: 4182-4187.
15. 1 receptor-expressing neurons in the striatum is associated with Parkinsonism but not dystonia. J Neurochem 110 (Suppl 2): 259.
16. 1-like dopamine receptors: Molecular biology and pharmacology. In: Di Chiara G, editor. Handbook of Experimental Pharmacology: Dopamine in the CNS 1. Heidelberg: Springer. p 122-158.
17. O'Sullivan GJ, O'Tuathaigh C, Tomiyama K, Koshikawa N, Waddington JL. 2010. Dopamine receptor subtypes and behaviour: From psychopharmacology to mutant models. In: Neve KA, editor. The Dopamine Receptors. Totowa, NJ: Humana. p 323-371.
18. Roos RA, Vegter-van der Vlis M, Hermans J, Elshove HM, Moll AC, van de Kamp JJ, Bruyn GW. 1991. Age at onset in Huntington's disease: Effect of line of inheritance and patient's sex. J Med Genet 28: 515-519.
19. 1 receptor mediates repetitive jaw movements in rats. Biol Psychiatry 44: 1178-1184.
20. Sokal RR, Rohlf FJ. 1995. Biometry. New York: WH Freeman & Co.
21. 2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30: 228-235.
22. 2-like receptor regulation. Eur J Pharmacol 418: 47-54.
23. 1A receptor 'knockout' mice. Neuropharmacology 42: 644-652.
24. 4 receptor or DARPP-32 transduction 'knockout'. Eur Neuropsychopharmacol 16: 437-445.
25. Tomiyama K, Song L, Kobayashi M, Kinsella A, Kanematsu T, Hirata M, Koshikawa N, Waddington JL. 2010. Orofacial movements in phospholipase C-related catalytically inactive protein (PRIP)-1/2 double knockout mice: Effect of the GABAergic agent diazepam and the D(1) dopamine receptor agonist SKF 83959. Synapse 64: 714-720.
26. Trosch RM. 2004. Neuroleptic-induced movement disorders: Deconstructing extrapyramidal symptoms. J Am Geriatr Soc 52 (Suppl 12): S266-S271.
27. Waddington JL. 1990. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: Phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 101: 431-447.
28. Waddington JL, Daly SA, Downes RP, Deveney AM, McCauley PG, O'Boyle KM. 1995. Behavioural pharmacology of 'D1-like' dopamine receptors: Further subtyping, new pharmacological probes and interactions with 'D2-like' receptors. Prog Neuro-Psychopharmacol Biol Psychiatry 19: 811-831.
29. Waddington JL, O'Tuathaigh C, O'Sullivan G, Tomiyama K, Koshikawa N, Croke DT. 2005. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: Insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology 181: 611-638.
30. Walker FO. 2007. Huntington's disease. Lancet 369: 218-228.
31. Whitty P, Owoeye O, Waddington JL. 2009. Neurological signs and involuntary movements in schizophrenia: Intrinsic to and informative on systems pathobiology. Schizophr Bull 35: 415-424.